NCT07356960Not yet recruiting
Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
Retrospective, Observational, Study on the Evaluation of the Real-world Outcome of Philadelphia-positive Acute Lymphoblastic Leukaemia Patients Treated With Ponatinib as First-line Treatment Under the Italian Law 648/96 (PONA4ALL Ph+)
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting. The main goal of the study is to assess the rate of complete molecular response (CMR) induced by ponatinib in patients treated under the regulations of Law 648/96, outside clinical trials. Patients who were treated with ponatinib as part of their regular medical care and completed the follow-up period will be included in the study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 103 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 2 Apr 2026
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Acute lymphoblastic leukaemia
- NCT number
- NCT07356960
What you commit to
- Study type: Observational
- Planned participants: 103
- From 2 Apr 2026 to the primary completion date, 30 Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patient is \> 18 years old;
- Patient was treated in first-line with ponatinib monotherapy or in association with chemotherapy or immunotherapy;
- Patient received ponatinib under the regulations of Law 648/96;
- \- Patient is alive and have at least 18 months of retrospective observation available from the start of ponatinib treatment, OR
- \- has died/lost to follow-up at any time after treatment initiation, regardless of the length of available follow-up;
- Signed informed consent, if applicable.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.